| Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk |
2018-08-17 |
| Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital |
2024-02-08 |
| Zetta Genomics–Univ Cambridge: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Univ Cambridge |
2024-02-08 |
| Zetta Genomics–Univ Cambridge: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Cambridge Enterprise |
2023-04-18 |
| Zetta Genomics–Univ Cambridge: investment, 202202 seed financing round totalling £2.5m incl co-investor Cambridge Enterprise |
2022-02-01 |
| Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m |
2024-02-08 |
| Zetta Genomics–SEVERAL: investment, 202304 2nd seed financing round £1.9m with led by Nina Capital |
2023-04-18 |
| Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital |
2022-02-01 |
| Zetta Genomics–Nina Capital: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Nina Capital |
2024-02-08 |
| Zetta Genomics–Nina Capital: investment, 202304 2nd seed financing round totalling £1.9m incl existing + lead investor Nina Capital |
2023-04-18 |
| Zetta Genomics–Nina Capital: investment, 202202 seed financing round totalling £2.5m incl lead investor Nina Capital |
2022-02-01 |
| Zetta Genomics–Apex Ventures: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Apex Ventures |
2024-02-08 |
| Zetta Genomics–Apex Ventures: investment, 202304 2nd seed financing round totalling £1.9m incl existing + co-investor Apex Ventures |
2023-04-18 |
| Zetta Genomics–Apex Ventures: investment, 202202 seed financing round totalling £2.5m incl co-investor Apex Medical |
2022-02-01 |
| Zelluna–Image Box: public relations, 201810 supply service existent by Image Box PR |
2018-10-24 |
| Zeincro–Excelya: investment, 202007 acquisition |
2020-06-07 |
| Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round |
2015-10-09 |
| Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones |
2018-07-24 |
| Zastra Innovations–Optibrium: drug discovery software, 201701– distribution excl of StarDrop s/w in India by Zastra Innovations |
2017-01-31 |
| Z Factor–SEVERAL: investment, 201705 financing round Series A £7m led by exising investor Medicxi |
2017-05-03 |
| Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi |
2019-06-04 |
| Yposkesi–Andrew Lloyd Associates: public relations, 201807 service existent by ALA |
2018-07-09 |
| Yourgene Bioscience–Premaitha: investment, 201612–201702 acquisition of Yourgene Bioscience Co Ltd by Premaitha Health plc |
2016-12-21 |
| Ynsect–SEVERAL: investment, 202010 financing round Series C extension to total of $372m led by Astanor Ventures |
2020-10-06 |
| Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($125m) led by Astanor Ventures |
2019-02-21 |
| Xund Solutions–SEVERAL: investment, 202209 seed financing round €6m co-led by MMC Ventures + MassMutual Ventures |
2022-09-29 |
| Xund Solutions–MMC Ventures: investment, 202209 seed financing round totalling €6m incl co-lead investor MMC Ventures |
2022-09-29 |
| Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners |
2017-01-05 |
| XenoGesis–Sygnature Discovery: investment, 202009 acquisition of XenoGesis by Sygnature Discovery |
2020-09-24 |
| Xenikos–SEVERAL: investment, 201805 financing round Series B $30m incl new investors Medicxi Ventures + RA Capital Management |
2018-05-15 |
| Xencor–Canale Communications: public relations, 201803 service existent by Canale |
2018-03-20 |
| Xconomy–Informa: investment, 201608 acquisition 100% £1m upfront + £1.5m milestones+deferred of Xconomy Inc by Informa |
2016-08-31 |
| Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals |
2019-01-22 |
| Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital |
2019-01-22 |
| Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group |
2019-01-22 |
| Westwicke Partners–ICR: investment, 201901 acquisition of Westwicke by ICR |
2019-01-03 |
| Wellington Partners–Consilium: public relations, 201907 service existent by CSC |
2019-07-31 |
| Waters–Spectris: analytical instruments, 201801– collab co-marketing agreem with Malvern Panalytical for Omnisec Reveal with Acquity APC system |
2018-01-16 |
| Waters–Omic Analytics: mass spectrometry software, 201703– license excl for sale of Proteolabels s/w with Progenesis QI for Proteomics |
2017-03-15 |
| Waters–Molecular Discovery: mass spectrometry s/w, 201808– collab product integration MetaSite + MassMetaSite s/w with UNIFI Platform |
2018-08-02 |
| Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines |
2018-10-16 |
| Voyager Therapeutics–Touchlight: dbDNA technology, 202211– license €na to use dbDNA technology in creation of novel capsids |
2022-11-15 |
| Vivet Therapeutics–Huntsworth: public relations, 201705 service existent by Citigate Dewe Rogerson |
2017-05-04 |
| ViveBiotech–Image Box: public relations, 202106 service existent by Image Box Communications |
2021-06-04 |
| Vivacta–Novartis: investment, 2012 acquisition by Novartis |
2012-01-01 |
| Vitarka Therapeutics–SEVERAL: investment, 202205 seed financing round £150k led by Discovery Park Ventures with £140k |
2022-05-09 |
| Vitarka Therapeutics–Discovery Park: investment, 202205 seed financing round totalling £150k incl £140k from Discovery Park Ventures |
2022-05-09 |
| Vitae–Allergan: investment, 201609 acquisition $640m of Vitae Pharmaceuticals Inc by Allergan plc |
2016-09-14 |
| VisusNano–United Kingdom (govt): grant, 202205c Innovate UK Biomedical Catalyst award £1.39m |
2022-05-09 |
| VisusNano–SEVERAL: investment, –202205– financing round Series A £1.5m expected to close shortly |
2022-05-09 |
| VisusNano–Discovery Park: investment, –202205– financing round Series A totalling £1.5m incl £100k from Discovery Park Ventures |
2022-05-09 |
| VirionHealth–Abingworth: investment, 201710 Series A financing up to £13m from Abingworth |
2017-10-12 |
| Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
| Vir Biotechnology–GSK: investment, 202004 equity investment $250m at $37.73/share (10% premium to share price 27 Mar 2020) in connection with collab |
2020-04-06 |
| Viela Bio–SEVERAL: investment, 201802 up to $250m funding from investor consortium at spin-out with AZ remaining largest minority shareholder |
2018-02-28 |
| ViaNautis Bio–UCB: investment, 202311 financing round Series A totalling $25m incl co-lead investor UCB Ventures |
2023-11-13 |
| ViaNautis Bio–SEVERAL: investment, 202311 financing round Series A $25m led by 4BIO Capital + BGF + UCB Ventures |
2023-11-13 |
| ViaNautis Bio–Origin Capital: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Origin Capital |
2023-11-13 |
| ViaNautis Bio–o2h: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor O2H |
2023-11-13 |
| ViaNautis Bio–Meltwind: investment, 202311 financing round Series A totalling $25m incl exisitng + co-investor Meltwind |
2023-11-13 |
| ViaNautis Bio–Cystic Fibrosis Foundation: investment, 202311 financing round Series A totalling $25m incl co-investor Cystic Fibrosis Foundation |
2023-11-13 |
| ViaNautis Bio–BGF: investment, 202311 financing round Series A totalling $25m incl co-lead investor BGF |
2023-11-13 |
| ViaNautis Bio–4BIO Ventures: investment, 202311 financing round Series A totalling $25m incl co-lead investor 4BIO Capital |
2023-11-13 |
| Vésale Bioscience–Andrew Lloyd Associates: public relations, 202301 service existent by ALA |
2023-01-17 |
| Vertex–Genomics plc: bioinformatics, 201808– collab expansion using human genetics + data science for target discovery + personalised medicine |
2018-08-30 |
| Verona Pharma–SEVERAL: investment, 201704 US IPO $78m with 5.768m ADSs at $13.5/ADS at Nasdaq Global Market |
2017-04-04 |
| Verona Pharma–Novo Group: investment, 201903 existent investment Novo Holdings owns 11.76% shareholding in Verona Pharma plc |
2019-03-21 |
| Verona Pharma–LCF Rothschild: investment, 201607 investment by EdRIP |
2016-07-01 |
| Verona Pharma–Arix Bioscience: investment, 2017 investment £1.8m during 2017 from existing investor Arix results in shareholding of 2.5% |
2017-01-01 |
| Vernalis–Ligand: investment, 201808– recommended cash takeover offer £32.8m with £0.062/share ANNOUNCED |
2018-08-09 |
| Verdel Instruments–United Kingdom (govt): investment, 201905 seed financing round totalling £230k incl investor Innovate UK |
2019-05-30 |
| Verdel Instruments–SEVERAL: investment, 201905 seed financing round £230k from Longwall Venture Partners + Innovate UK |
2019-05-30 |
| Verdel Instruments–Longwall Venture Partners: investment, 201905 seed financing round totalling £230k incl £100k from Longwall Ventures |
2019-05-30 |
| Vera Therapeutics–Abingworth: investment, 202102 investment existent by Abingworth Bioventures 8 |
2021-02-03 |
| VenBio–UDG Healthcare: public relations, 202004 service existent by Canale Communciations |
2020-04-03 |
| VelosBio–Sofinnova: investment, 201810 financing round Series A totalling $58m incl new + co-lead investor Sofinnova Ventures |
2018-10-01 |
| VelosBio–SEVERAL: investment, 201810 financing round Series A $58m co-led by new investors Arix Bioscience + Sofinnova Ventures |
2018-10-01 |
| VelosBio–Merck (US): investment, 202011–202012 acquisition $2.75b in cash of VelosBio by Merck |
2020-11-05 |
| VelosBio–Arix Bioscience: investment, 201810 financing round Series A totalling $58m incl $11m from new + co-lead investor Arix Bioscience |
2018-10-01 |
| Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201606 financing round totalling $50m incl new investor Rock Springs Capital |
2016-06-06 |
| Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health |
2018-12-24 |
| Vedanta Biosciences–PureTech Health: investment, 201606 financing round totalling $50m incl investor PureTech Health plc |
2016-06-06 |
| Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management |
2018-12-24 |
| Vedanta Biosciences–Invesco: investment, 201606 financing round totalling $50m incl new investor Invesco Asset Management |
2016-06-06 |
| Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201606 financing round totalling $50m incl new investor Health for Life Capital (Seventure) |
2016-06-06 |
| Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS |
2018-12-24 |
| Vectura–Philip Morris: investment, 202107– acquisition recommended cash tender offer £852m at150p/share |
2021-07-09 |
| VectorY–Instinctif Partners: public relations, 202106 service existent by Instinctif |
2021-06-15 |
| Vector Neurosciences–MeiraGTx: investment, 201810 acquisition in all-stock transaction by MeiraGTx |
2018-10-05 |
| VectivBio–Kreos Capital: credit, 202203– loan facility up to $75m with minimum draw down of $10m |
2022-03-30 |
| VaxEquity–Scius Communications: public relations, 202109 supply service existent by Scius Communications |
2021-09-23 |
| VaxEquity–Morningside: investment, 202109 equity investment by Morningside Ventures |
2021-09-23 |
| VaxEquity–AstraZeneca: investment, 202109 equity investment by AstraZeneca in connection with strategic research collab |
2021-09-23 |
| Vasopharm–Optimum Strategic Communications: public relations, 201907 service existent by Optimum |
2019-07-11 |
| VarmX–Instinctif Partners: public relations, 202007 service existent by Instinctif |
2020-07-08 |
| Valo Therapeutics–Scius Communications: public relations, 202006 supply service existent by Scius Communications |
2020-06-08 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
